IL‐1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

IL‐1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia

Published:2021-10-09 Issue:3 Volume:69 Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Naviglio Samuele¹^ORCID,Zanella Giada¹^ORCID,Verzegnassi Federico¹^ORCID,Kiren Valentina¹,Giurici Nagua¹,Sieni Elena²^ORCID,Coniglio Maria Luisa²,Valencic Erica³,Tommasini Alberto³⁴,Rabusin Marco¹

Affiliation:

1. Pediatric Hematology‐Oncology Institute for Maternal and Child Health IRCCS “Burlo Garofolo,” Trieste Italy

2. Pediatric Hematology/Oncology Department Meyer Children's University Hospital Florence Italy

3. Department of Pediatrics Institute for Maternal and Child Health IRCCS “Burlo Garofolo,” Trieste Italy

4. Department of Medicine, Surgery, and Health Sciences University of Trieste Trieste Italy

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29404

Reference15 articles.

1. Therapeutic Role of Anakinra, an Interleukin-1 Receptor Antagonist, in the Management of Secondary Hemophagocytic Lymphohistiocytosis/Sepsis/Multiple Organ Dysfunction/Macrophage Activating Syndrome in Critically Ill Children*

2. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence

3. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease

4. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

5. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2022-06